Equity Overview
Price & Market Data
Price: $1.25
Daily Change: -$0.0051 / 0.41%
Range: $1.25 - $1.35
Market Cap: $62,120,876
Volume: 10,108
Performance Metrics
1 Week: -7.30%
1 Month: 0.79%
3 Months: -37.90%
6 Months: -48.37%
1 Year: -79.81%
YTD: -38.35%
Company Details
Employees: 107
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.